ArticleOncogene2022
Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment.
Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- LEF1/NFE2L3/TACC1 axis activates the AKT-mTOR pathway to promote the progression of esophageal squamous cell carcinoma.Journal of thoracic disease · 2026Article
- A comprehensive review of the emerging role of NRF3 in ovarian cancer tumorigenesis and progression.Journal of ovarian research · 2026Review
- Unraveling Signaling Pathways in Immune Microenvironment Crosstalk to Overcome Immunotherapy Resistance in Colorectal Cancer.Human mutation · 2026Review
- Article
- Dietary restriction-responsive genes define prognostic subtypes and predict metastasis in colorectal cancer.Translational cancer research · 2025Article
- Modeling combinatorial regulation from single-cell multi-omics provides regulatory units underpinning cell type landscape using cRegulon.Genome biology · 2025Article
- An Integrative Genomics Approach for the Discovery of Potential Clinically Actionable Diagnostic and Prognostic Biomarkers in Colorectal Cancer.Biomedicines · 2025Article
- A METTL3-NFE2L3 axis mediates tumor stemness and progression in lung adenocarcinoma.Science advances · 2025Article
- NAT10 promotes the progression of clear cell renal cell carcinoma by regulating ac4C acetylation of NFE2L3 and activating AKT/GSK3β signaling pathway.Cell death & disease · 2025Article
- Mast cells: key players in digestive system tumors and their interactions with immune cells.Cell death discovery · 2025Review
- TRP-related gene signatures predict survival and the immune microenvironment in rectal cancer: a comprehensive bioinformatics study.Frontiers in immunology · 2025Article
- Exploratory research on therapeutic agents combined with early diagnostic biomarkers for colorectal cancer.Frontiers in pharmacology · 2025Article
- NRF3 suppresses the malignant progression of TNBC by promoting M1 polarization of macrophages via ROS/HMGB1 axis.Cancer biology & therapy · 2024Article
- Deciphering tumour microenvironment and elucidating the origin of cancer cells in ovarian clear cell carcinoma.bioRxiv : the preprint server for biology · 2024Article
- Identification of potential biomarkers for aging diagnosis of mesenchymal stem cells derived from the aged donors.Stem cell research & therapy · 2024Article
- Identification roles of NFE2L3 in digestive system cancers.Journal of cancer research and clinical oncology · 2024Article
- Identification of prognostic risk score of disulfidptosis-related genes and molecular subtypes in glioma.Biochemistry and biophysics reports · 2024Article
- New insight into the CNC-bZIP member, NFE2L3, in human diseases.Frontiers in cell and developmental biology · 2024Review
- NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5.EMBO molecular medicine · 2023Article
- An alternative extension of telomeres related prognostic model to predict survival in lower grade glioma.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
We investigated the role of the NFE2L3 transcription factor in inflammation-induced colorectal cancer. Our studies revealed that Nfe2l3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.